Stereotaxis (NYSEAMERICAN:STXS) Releases Quarterly Earnings Results, Meets Estimates

Key Points

• Stereotaxis met EPS expectations at a $0.05 loss per share, but quarterly revenue of $7.67 million fell short of the $8.35 million consensus estimate. The company reported a $4.5 million net loss and negative free cash flow of $3.7 million.
• Recurring revenue reached $6.2 million, supported by the MAGiC catheter launch and a 270% sequential increase in robotic catheter revenue. Management expects recurring revenue to grow to approximately $7 million in Q3 and $8 million in Q4 as catheter production expands.
• Management reiterated its goal of achieving cash-flow profitability in the first half of 2027 without additional financing, while highlighting new GenesisX and Synchrony orders and longer-term opportunities in mobile robotics, pulse-field ablation, AI-enabled surgery, and the Robocath acquisition.

Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05), FiscalAI reports. Stereotaxis had a negative net margin of 69.50% and a negative return on equity of 163.30%. The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $8.35 million.

Here are the key takeaways from Stereotaxis' conference call:

• Recurring revenue reached $6.2 million in Q2, driven by the launch of MAGiC and a 270% sequential increase in robotic catheter revenue. Management expects recurring revenue to rise to approximately $7 million in Q3 and $8 million in Q4.
• MAGiC adoption is expanding, with roughly a dozen U.S. hospitals approved to purchase the catheter and procedure-level disposable revenue generally in the $5,000–$8,000-plus range. Demand currently exceeds supply, but the company expects about $1 million of incremental catheter revenue in each of the next two quarters as manufacturing ramps.
• Stereotaxis received its first U.S. GenesisX order and expects installation this fall alongside a non-modified X-ray, supporting formal compatibility with that manufacturer. Synchrony also generated initial orders and is expected to contribute more than $1 million of system revenue per quarter in the near term.
• Q2 revenue was $7.7 million, down year over year because no robotic system was delivered, while the company posted a $4.5 million net loss and $3.7 million of negative free cash flow. Gross margins remained pressured by low manufacturing volumes, and management acknowledged ongoing adoption barriers including catheter supply, GenesisX validation, and X-ray compatibility.
• Management reiterated its expectation of reaching cash-flow profitability in the first half of 2027 without additional financing, assuming continued catheter adoption and modest system sales. The company also highlighted longer-term growth opportunities from a wireless/mobile robot, pulse-field-ablation catheters, AI-enabled surgery, and the recently completed Robocath acquisition.

Stereotaxis Stock Performance

Shares of Stereotaxis stock traded down $0.06 during trading on Wednesday, hitting $1.40. The company's stock had a trading volume of 1,372,072 shares, compared to its average volume of 608,693. Stereotaxis has a 52 week low of $1.24 and a 52 week high of $3.59. The company has a market capitalization of $137.10 million, a PE ratio of -5.83 and a beta of 1.37. The company has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.87.

Institutional Investors Weigh In On Stereotaxis

Hedge funds and other institutional investors have recently bought and sold shares of the business. WealthPLAN Partners LLC purchased a new position in shares of Stereotaxis during the fourth quarter valued at approximately $29,000. BNP Paribas Financial Markets increased its position in Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company's stock valued at $36,000 after buying an additional 5,910 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Stereotaxis during the third quarter valued at $38,000. HRT Financial LP bought a new stake in Stereotaxis in the fourth quarter worth $42,000. Finally, Moneta Group Investment Advisors LLC purchased a new stake in shares of Stereotaxis in the third quarter worth $43,000. Hedge funds and other institutional investors own 45.35% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on STXS. Citigroup reiterated a "market outperform" rating on shares of Stereotaxis in a report on Wednesday, June 3rd. TD Cowen lowered their target price on Stereotaxis from $5.00 to $3.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Piper Sandler restated an "overweight" rating and set a $3.50 price target (down from $4.00) on shares of Stereotaxis in a research report on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, Stereotaxis currently has an average rating of "Buy" and a consensus target price of $3.70.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company's flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source